Cited 0 times in
3'-Sialyllactose Protects SW1353 Chondrocytic Cells From Interleukin-1β-Induced Oxidative Stress and Inflammation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조성래 | - |
dc.date.accessioned | 2021-05-26T16:52:57Z | - |
dc.date.available | 2021-05-26T16:52:57Z | - |
dc.date.issued | 2021-04 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/182878 | - |
dc.description.abstract | Osteoarthritis (OA) is a major degenerative joint disease. Oxidative stress and inflammation play key roles in the pathogenesis of OA. 3'-Sialyllactose (3'-SL) is derived from human milk and is known to regulate a variety of biological functions related to immune homeostasis. This study aimed to investigate the therapeutic mechanisms of 3'-SL in interleukin-1β (IL-1β)-treated SW1353 chondrocytic cells. 3'-SL potently suppressed IL-1β-induced oxidative stress by increasing the levels of enzymatic antioxidants. 3'-SL significantly reversed the IL-1β mediated expression levels of reactive oxygen species in IL-1β-stimulated chondrocytic cells. In addition, 3'-SL could reverse the increased levels of inflammatory markers such as nitrite, prostaglandin E2, inducible nitric oxide synthase, cyclooxygenase-2, IL-1β, and IL-6 in IL-1β-stimulated chondrocytic cells. Moreover, 3'-SL significantly inhibited the apoptotic process, as indicated by the downregulation of the pro-apoptotic protein Bax, upregulation of the anti-apoptotic protein Bcl-2 expression, and significant reduction in the number of TUNEL-positive cells in the IL-1β-treated chondrocytic cells. Furthermore, 3'-SL reversed cartilage destruction by decreasing the release of matrix metalloproteinases (MMP), such as MMP1, MMP3, and MMP13. In contrast, 3'-SL significantly increased the expression levels of matrix synthesis proteins, such as collagen II and aggrecan, in IL-1β-treated chondrocytic cells. 3'-SL dramatically suppressed the activation of mitogen-activated protein kinases (MAPK) and phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT)/nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathways, which are related to the pathogenesis of OA. Taken together, our data suggest that 3'-SL alleviates IL-1β-induced OA pathogenesis via inhibition of activated MAPK and PI3K/AKT/NF-κB signaling cascades with the downregulation of oxidative stress and inflammation. Therefore, 3'-SL has the potential to be used as a natural compound for OA therapy owing to its ability to activate the antioxidant defense system and suppress inflammatory responses. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Frontiers Media | - |
dc.relation.isPartOf | FRONTIERS IN PHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | 3'-Sialyllactose Protects SW1353 Chondrocytic Cells From Interleukin-1β-Induced Oxidative Stress and Inflammation | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Rehabilitation Medicine (재활의학교실) | - |
dc.contributor.googleauthor | Ahreum Baek | - |
dc.contributor.googleauthor | So Hee Jung | - |
dc.contributor.googleauthor | Soonil Pyo | - |
dc.contributor.googleauthor | Soo Yeon Kim | - |
dc.contributor.googleauthor | Seongmoon Jo | - |
dc.contributor.googleauthor | Lila Kim | - |
dc.contributor.googleauthor | Eun Young Lee | - |
dc.contributor.googleauthor | Sung Hoon Kim | - |
dc.contributor.googleauthor | Sung-Rae Cho | - |
dc.identifier.doi | 10.3389/fphar.2021.609817 | - |
dc.contributor.localId | A03831 | - |
dc.relation.journalcode | J03340 | - |
dc.identifier.eissn | 1663-9812 | - |
dc.identifier.pmid | 33912037 | - |
dc.subject.keyword | 3′-sialyllactose | - |
dc.subject.keyword | apoptosis | - |
dc.subject.keyword | inflammation | - |
dc.subject.keyword | matrix metalloproteinases | - |
dc.subject.keyword | osteoarthritis | - |
dc.subject.keyword | oxidative stress | - |
dc.contributor.alternativeName | Cho, Sung Rae | - |
dc.contributor.affiliatedAuthor | 조성래 | - |
dc.citation.volume | 12 | - |
dc.citation.startPage | 609817 | - |
dc.identifier.bibliographicCitation | FRONTIERS IN PHARMACOLOGY, Vol.12 : 609817, 2021-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.